In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
Here are two options investors should consider: Johnson & Johnson ( JNJ 0.09%) and Merck ( MRK 1.54%). These two healthcare ...
Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...
Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per ...
US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...
MedPage Today on MSN
Preservatives and Cancer; Pre-Op Therapy Gains Momentum; Speedier Myeloma Approvals
News, features, and commentary about cancer-related issues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results